Parallel Advisors’s vTv Therapeutics VTVT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.43K Hold
38
﹤0.01% 3607
2026
Q1
$1.51K Hold
38
﹤0.01% 3453
2025
Q4
$1.52K Hold
38
﹤0.01% 3205
2025
Q3
$887 Hold
38
﹤0.01% 3250
2025
Q2
$570 Hold
38
﹤0.01% 3290
2025
Q1
$658 Hold
38
﹤0.01% 3195
2024
Q4
$525 Hold
38
﹤0.01% 3216
2024
Q3
$515 Hold
38
﹤0.01% 3180
2024
Q2
$671 Hold
38
﹤0.01% 3036
2024
Q1
$894 Hold
38
﹤0.01% 2956
2023
Q4
$437 Hold
38
﹤0.01% 3078
2023
Q3
$717 Hold
38
﹤0.01% 3037
2023
Q2
$1.11K Hold
38
﹤0.01% 2907
2023
Q1
$1.21K Hold
38
﹤0.01% 2911
2022
Q4
$979 Hold
38
﹤0.01% 2902
2022
Q3
$1K Hold
38
﹤0.01% 3045
2022
Q2
$1K Hold
38
﹤0.01% 2883
2022
Q1
$1K Hold
38
﹤0.01% 2866
2021
Q4
$1K Hold
38
﹤0.01% 2977
2021
Q3
$2K Hold
38
﹤0.01% 2746
2021
Q2
$3K Hold
38
﹤0.01% 2503
2021
Q1
$4K Hold
38
﹤0.01% 2295
2020
Q4
$3K Hold
38
﹤0.01% 2235
2020
Q3
$3K Hold
38
﹤0.01% 2231
2020
Q2
$3K Buy
+38
New +$3.75K ﹤0.01% 2134

Other funds holding VTVT

Parallel Advisors's VTVT Position: Q2 2026 in Review

Parallel Advisors held its vTv Therapeutics (VTVT) position steady in Q2 2026 at 38 shares worth $1.43K. The position accounts for ﹤0.01% of the portfolio, ranked #3607.

Parallel Advisors first reported a position in VTVT in Q2 2020 and has held it in 25 quarters since. The position peaked at $4K in Q1 2021. 12 funds tracked by Wall St. Rank hold VTVT as of Q2 2026.

  • Parallel Advisors held 38 shares of vTv Therapeutics worth $1.43K as of Q2 2026.
  • Parallel Advisors left its vTv Therapeutics share count unchanged in Q2 2026.
  • vTv Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3607 holding.
  • Parallel Advisors first reported a position in vTv Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • Parallel Advisors's vTv Therapeutics position peaked at $4K in Q1 2021.
  • 12 funds tracked by Wall St. Rank held vTv Therapeutics as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.